Action Viveve Medical - VIVE

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,2201

Prix Achat

0,2201

Prix Vente

0,23

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

0,2201

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

- Company reports $18.5 million in preliminary full year 2018 revenue, representing 21% year-over-year...

Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

ENGLEWOOD, Colo., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical...

Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

- Sites to continue enrollment up to 250 patients in sexual function trial - ENGLEWOOD, Colo., Dec. 20...

Viveve Announces Closing of Public Offering of Shares of Common Stock

ENGLEWOOD, Colo., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a...

Viveve Announces Pricing of Public Offering of Shares of Common Stock

ENGLEWOOD, Colo., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a...

Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

— 72% of women treated experienced an improvement in the one-hour pad weight with an overall mean improvement...

Viveve Announces Proposed Public Offering of Shares of Common Stock

ENGLEWOOD, Colo., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (“Viveve”) (NASDAQ: VIVE), a...

Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

Twelve-month data from the SUI feasibility study to be presented ENGLEWOOD, Colo., Nov. 29, 2018 (GLOBE...

Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

Company awarded sixth place overall and is only medical device company listed in the top ten ENGLEWOOD...

Viveve to Present at Stifel 2018 Healthcare Conference

ENGLEWOOD, Colo., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Viveve Medical, Inc. (NASDAQ: VIVE), a medical...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

VIVE - Frequently Asked Questions (FAQ)

What is the current Viveve Medical share price?

The current share price of Viveve Medical is US$ 0,2201

What is the 1 year trading range for Viveve Medical share price?

Viveve Medical has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JTAIJet AI Inc	US$ 6,02 (133,33%)	104,48M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	254,39M
WRDWeRide Inc	US$ 31,4877 (83,39%)	21,07M
INLFINLIF Limited	US$ 16,27 (80,58%)	7,68M
MBRXMoleculin Biotech Inc	US$ 2,1201 (66,94%)	136,66M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3,08 (-56,31%)	425,19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3,36 (-52,68%)	5,21k
CSAICloudastructure Inc	US$ 19,0001 (-49,58%)	1,01M
NEXNNexxen International Ltd	US$ 10,30 (-49,16%)	160,99k
BSLKBolt Projects Holdings Inc	US$ 0,6626 (-46,13%)	13,07M
CNSPCNS Pharmaceuticals Inc	US$ 0,1415 (31,26%)	489,28M
MGOLMGO Global Inc	US$ 0,7176 (-15,08%)	417,31M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	254,39M
INTCIntel Corporation	US$ 23,60 (-2,20%)	230,26M
NVDANVIDIA Corporation	US$ 138,85 (2,63%)	194,99M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Viveve Medical Inc (VIVE)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

VIVE Dernières nouvelles

Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

Viveve Announces Closing of Public Offering of Shares of Common Stock

Viveve Announces Pricing of Public Offering of Shares of Common Stock

Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

Viveve Announces Proposed Public Offering of Shares of Common Stock

Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

Viveve to Present at Stifel 2018 Healthcare Conference

VIVE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Viveve Medical Inc (VIVE) Cours

Viveve Medical Inc (VIVE)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

VIVE Dernières nouvelles

Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

Viveve Announces Closing of Public Offering of Shares of Common Stock

Viveve Announces Pricing of Public Offering of Shares of Common Stock

Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

Viveve Announces Proposed Public Offering of Shares of Common Stock

Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

Viveve to Present at Stifel 2018 Healthcare Conference

VIVE - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS